Amgen, Takeda deal

Takeda said it returned its Japanese rights to fulranumab ( AMG 403) and trebananib ( AMG

Read the full 161 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE